Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Abstract

Substituted heteroaromatic compounds of formula (A) wherein X is N or CH; in which (a) represents a fused 5, 6 or 7-membered heterocyclic ring and R,is a group ZR,wherein Z is joined to R,through a (CH,)p group in which p is 0, 1, or 2 and Z represents a group V(CH,), V(CF,), (CH,)V, (CF,)V, V(CRR′), V(CHR) or V where R and R′ are each C,alkyl and in which V is a hydrocarbyl group containing 0, 1 or 2 carbon atoms, carbonyl, dicarbonyl, CH(OH), CH(CN), sulphonamide, amide, O, S(O),or NR,where R,is hydrogen or R,is C,alkyl; and R,is an optionally substituted C,cycloalkyl or an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety; or R,is a group ZR,in which Z is NR,, and NR,and R,together form an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety, are protein tyrosine kinase inhibitors. The compounds are described, as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of psoriasis, fibrosis, atherosclerosis, restenosis, auto-immune disease, allergy, asthma, transplantation rejection, inflammation, thrombosis, nervous system diseases, and cancer.